FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918678300> ?p ?o ?g. }

• W2918678300 endingPage "3173" @default.
• W2918678300 startingPage "3173" @default.
• W2918678300 abstract "Abstract The B-cell maturation antigen (BCMA) is selectively expressed by cells of the B-lineage, including multiple myeloma (MM) cells, and constitutes a promising target for immunotherapeutic approaches. At present, BCMA is being evaluated as target for immunotherapeutic approaches, such as CAR T cells and bispecific antibodies, which have demonstrated promising results in phase I clinical trials. The utilization of cytotoxic T cells bearing T-cell receptors against BCMA constitutes an alternative promising approach to target MM cells. Therefore, the identification of BCMA-derived peptides that are naturally presented by human leukocyte antigens (HLA) and thus can serve as target structures for CD8+ T cells, is indispensable. In a previous study, we characterized the immunopeptidomic landscape of MM by mass spectrometry-based analysis of naturally presented HLA ligands from primary MM samples and MM cell lines (Walz et al., Blood, 2015). Comparative HLA peptidome profiling of the MM-derived HLA ligands versus the immunopeptidome of numerous benign samples from different tissues identified several strictly MM-associated antigens. Here, we evaluated this dataset for the presence of BCMA-derived MM-exclusive antigens and identified two HLA class I-restricted, BCMA-derived peptides in the immunopeptidome of our cohort comprising 15 primary MM samples and MM cell lines. Notably, one of these peptides showes strictly MM-associated presentation and was never detected on any benign tissues according to our extensive immunopeptidome database (135,354 HLA ligands originating from 16,626 source proteins detected in 337 samples from various benign tissues including blood, bone marrow, lung, kidney, liver, and spleen). This HLA-B*18-restricted ligand P(BCMA)B*18 is represented in 20% (3/15) of the analyzed MM immunopeptidomes. For immunological characterization of the P(BCMA)B*18 peptide, we performed in vitro artificial antigen-presenting cell-based priming experiments engaging naïve CD8+ T cells obtained from healthy volunteers (HV). Induction of tetramer-positive T-cell populations with frequencies ranging from 0.1-2.9% of viable CD8+ T cells was observed for all analyzed healthy whole blood donors, which demonstrates the immunogenicity of P(BCMA)B*18. Subsequently, we functionally characterized the induced P(BCMA)B*18-specific CD8+ T cells using intracellular cytokine staining. Upon stimulation with P(BCMA)B*18, we observed an increased IFNγ and TNF production specifically in the peptide-specific CD8+ T cells. In addition, the degranulation marker CD107a was found to be upregulated in the analyzed tetramer-positive T cells, confirming the activity of CD8+ T cells upon peptide-stimulation. Priming experiments using naïve CD8+ T cells obtained from MM patients as well as in vitro cytotoxicity assays with polyclonal peptide-specific effector T cells are presently ongoing in order to assess the capacity of P(BCMA)B*18-specific CD8+ T cells to induce antigen-specific cell lysis. Taken together, we identified a naturally presented and MM-associated, BCMA-derived peptide, which constitutes a promising target for tailored T cell-based immunotherapeutic approaches. Disclosures Salih: Several patent applications: Patents & Royalties: e.g. EP3064507A1. Kowalewski:Immatics Biotechnologies GmbH: Employment. Weisel:Amgen, BMS, Celgene, Janssen, and Takeda: Honoraria; Amgen, BMS, Celgene, Janssen, Juno, Sanofi, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen, Celgene, Janssen, and Sanofi: Research Funding." @default.
• W2918678300 created "2019-03-11" @default.
• W2918678300 creator A5012388687 @default.
• W2918678300 creator A5012626247 @default.
• W2918678300 creator A5017270986 @default.
• W2918678300 creator A5022522496 @default.
• W2918678300 creator A5026255080 @default.
• W2918678300 creator A5037039636 @default.
• W2918678300 creator A5050313784 @default.
• W2918678300 creator A5066624700 @default.
• W2918678300 creator A5090087637 @default.
• W2918678300 creator A5090153362 @default.
• W2918678300 creator A5091779940 @default.
• W2918678300 date "2018-11-29" @default.
• W2918678300 modified "2023-10-16" @default.
• W2918678300 title "Analysis of the Multiple Myeloma HLA Peptidome Identifies a Naturally Presented Bcma-Derived Peptide As an Immunogenic T-Cell Epitope for Immunotherapeutic Approaches" @default.
• W2918678300 doi "https://doi.org/10.1182/blood-2018-99-113473" @default.
• W2918678300 hasPublicationYear "2018" @default.
• W2918678300 type Work @default.
• W2918678300 sameAs 2918678300 @default.
• W2918678300 citedByCount "0" @default.
• W2918678300 crossrefType "journal-article" @default.
• W2918678300 hasAuthorship W2918678300A5012388687 @default.
• W2918678300 hasAuthorship W2918678300A5012626247 @default.
• W2918678300 hasAuthorship W2918678300A5017270986 @default.
• W2918678300 hasAuthorship W2918678300A5022522496 @default.
• W2918678300 hasAuthorship W2918678300A5026255080 @default.
• W2918678300 hasAuthorship W2918678300A5037039636 @default.
• W2918678300 hasAuthorship W2918678300A5050313784 @default.
• W2918678300 hasAuthorship W2918678300A5066624700 @default.
• W2918678300 hasAuthorship W2918678300A5090087637 @default.
• W2918678300 hasAuthorship W2918678300A5090153362 @default.
• W2918678300 hasAuthorship W2918678300A5091779940 @default.
• W2918678300 hasBestOaLocation W29186783001 @default.
• W2918678300 hasConcept C147483822 @default.
• W2918678300 hasConcept C153911025 @default.
• W2918678300 hasConcept C154317977 @default.
• W2918678300 hasConcept C167672396 @default.
• W2918678300 hasConcept C185592680 @default.
• W2918678300 hasConcept C188280979 @default.
• W2918678300 hasConcept C195616568 @default.
• W2918678300 hasConcept C202751555 @default.
• W2918678300 hasConcept C203014093 @default.
• W2918678300 hasConcept C55493867 @default.
• W2918678300 hasConcept C86803240 @default.
• W2918678300 hasConceptScore W2918678300C147483822 @default.
• W2918678300 hasConceptScore W2918678300C153911025 @default.
• W2918678300 hasConceptScore W2918678300C154317977 @default.
• W2918678300 hasConceptScore W2918678300C167672396 @default.
• W2918678300 hasConceptScore W2918678300C185592680 @default.
• W2918678300 hasConceptScore W2918678300C188280979 @default.
• W2918678300 hasConceptScore W2918678300C195616568 @default.
• W2918678300 hasConceptScore W2918678300C202751555 @default.
• W2918678300 hasConceptScore W2918678300C203014093 @default.
• W2918678300 hasConceptScore W2918678300C55493867 @default.
• W2918678300 hasConceptScore W2918678300C86803240 @default.
• W2918678300 hasIssue "Supplement 1" @default.
• W2918678300 hasLocation W29186783001 @default.
• W2918678300 hasOpenAccess W2918678300 @default.
• W2918678300 hasPrimaryLocation W29186783001 @default.
• W2918678300 hasRelatedWork W2001280522 @default.
• W2918678300 hasRelatedWork W2001648299 @default.
• W2918678300 hasRelatedWork W2008949385 @default.
• W2918678300 hasRelatedWork W2028084086 @default.
• W2918678300 hasRelatedWork W2037082443 @default.
• W2918678300 hasRelatedWork W2040554954 @default.
• W2918678300 hasRelatedWork W2053177727 @default.
• W2918678300 hasRelatedWork W2060246599 @default.
• W2918678300 hasRelatedWork W2154326599 @default.
• W2918678300 hasRelatedWork W3030900991 @default.
• W2918678300 hasVolume "132" @default.
• W2918678300 isParatext "false" @default.
• W2918678300 isRetracted "false" @default.
• W2918678300 magId "2918678300" @default.
• W2918678300 workType "article" @default.